HORIZON (OP-106) versus MAMMOTH: An indirect comparison of efficacy outcomes for patients with relapsed/refractory multiple myeloma refractory (RRMM) to anti-CD38 monoclonal antibody therapy treated with melflufen plus dexamethasone versus conventional agents Meeting Abstract
| Authors: | Creixenti, J. B.; Mateos, M. V.; Oriol, A.; Larocca, A.; Cavo, M.; Rodriguez-Otero, P.; Leleu, X.; Norkin, M.; Nadeem, O.; Hiemenz, J. W.; Hassoun, H.; Touzeau, C.; Amor, A. A.; Paner, A.; Maisel, C.; Mazumder, A.; Raptis, A.; Puig, N.; Zavisic, S.; Thuresson, M.; Harmenberg, J.; Richardson, P. G. |
| Abstract Title: | HORIZON (OP-106) versus MAMMOTH: An indirect comparison of efficacy outcomes for patients with relapsed/refractory multiple myeloma refractory (RRMM) to anti-CD38 monoclonal antibody therapy treated with melflufen plus dexamethasone versus conventional agents |
| Meeting Title: | 62nd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 136 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Dec 5-8 |
| Meeting Location: | Virtual |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2020-11-05 |
| Language: | English |
| ACCESSION: | WOS:000607547206085 |
| DOI: | 10.1182/blood-2020-137164 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 2 -- Source: Wos |
